JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morigi, M.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morigi, M.
Right arrow Articles by Remuzzi, G.

Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice

M Morigi, D Macconi, E Riccardi, P Boccardo, P Zilio, T Bertani and G Remuzzi

Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.

Platelet-activating factor (PAF) has been suggested recently to play an important role in immune glomerulonephritis, favoring the formation of immune deposits in glomeruli and contributing to the local inflammatory reaction. Here we sought to investigate whether urinary PAF excretion was modified in New Zealand Black x New Zealand White mice a model of genetically determined immune complex disease which mimics systemic lupus in humans and whether changes in PAF urinary excretion values correlated with the extent of proteinuria. To clarify the possible "in vivo" relevance of these findings we evaluated whether PAF receptor antagonist has any influence on the evolution of renal disease and survival of these mice. Our results showed that: 1) in lupus mice urinary PAF excretion increased progressively with age in New Zealand Black x White; 2) the increase in PAF excretion correlated with the severity of proteinuria; and 3) the chronic administration of a PAF receptor antagonist [L-659,989 [(+/- )-trans-2-(3-methoxy-5- methylsulfonyl-4-propoxyphenyl)-5- (3,4,5- trimethoxyphenyl)tetrahydrofuran]] starting from 26 weeks of age significantly delayed the onset of proteinuria and prolonged survival.

Volume 258, Issue 2, pp. 601-606, 08/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Am. Coll. Nutr.Home page
W. F. Clark, C. Kortas, A. P. Heidenheim, J. Garland, E. Spanner, and A. Parbtani
Flaxseed in Lupus Nephritis: A Two-Year Nonplacebo-Controlled Crossover Study
J. Am. Coll. Nutr., April 1, 2001; 20(2): 143 - 148.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
W F Clark, A D Muir, N D Westcott, and A Parbtani
A novel treatment for lupus nephritis: lignan precursor derived from flax
Lupus, July 1, 2000; 9(6): 429 - 436.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. G. Greenberg and K. E. Clark
Hemodynamic effects of platelet-activating factor in nonpregnant and pregnant sheep
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1999; 277(4): R996 - R1001.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.